Epigenetic therapy in urologic cancers: an update on clinical trials.
Ontology highlight
ABSTRACT: Epigenetic dysregulation is one of many factors that contribute to cancer development and progression. Numerous epigenetic alterations have been identified in urologic cancers including histone modifications, DNA methylation changes, and microRNA expression. Since these changes are reversible, efforts are being made to develop epigenetic drugs that restore the normal epigenetic patterns of cells, and many clinical trials are already underway to test their clinical potential. In this review we analyze multiple clinical trials (n=51) that test the efficacy of these drugs in patients with urologic cancers. The most frequently used epigenetic drugs were histone deacetylase inhibitors followed by antisense oligonucleotides, DNA methyltransferase inhibitors and histone demethylase inhibitors, th
SUBMITTER: Faleiro I
PROVIDER: S-EPMC5355359 | biostudies-literature | 2017 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA